Literature DB >> 23347256

Functional roles of tumor necrosis factor-related apoptosis-inducing ligand-DR5 interaction in B16F10 cells by activating the nuclear factor-κB pathway to induce metastatic potential.

Kei Takahashi1, Kazuyoshi Takeda, Ikuo Saiki, Tatsuro Irimura, Yoshihiro Hayakawa.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been recognized as a promising target for cancer therapy because it can induce apoptotic cell death in tumor cells but not normal cells. Although TRAIL shows specific tumoricidal activity, resistance to TRAIL-induced apoptosis in some tumor cells has been considered a clinical obstacle of its application. It has been shown that TRAIL provides inflammatory signals that may contribute to the TRAIL-resistance of cancer cells; however, it is not known whether TRAIL itself is involved in malignant cancer cell behavior. In the present study, we examined the functional role of TRAIL in B16F10 mouse melanoma cells, which are totally insensitive to TRAIL-induced apoptosis. By establishing B16F10 cells stably expressing the nuclear factor-κB (NFκB)-luciferase reporter gene, we found that TRAIL can activate NFκB through its death receptor DR5 in B16F10 cells. Furthermore, TRAIL-DR5 interaction not only promoted malignant behaviors of B16F10 cells, such as cell proliferation and MMP-9 production, but also induced lung metastasis of B16F10 cells in vivo. These findings may imply a contrary role for the TRAIL-DR5 pathway in the inflammatory tumor microenvironment, in its ability to induce the metastatic potential of B16F10 melanoma cells instead of inducing apoptosis.
© 2013 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347256     DOI: 10.1111/cas.12112

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  8 in total

1.  From Proteomic Mapping to Invasion-Metastasis-Cascade Systemic Biomarkering and Targeted Drugging of Mutant BRAF-Dependent Human Cutaneous Melanomagenesis.

Authors:  Aikaterini F Giannopoulou; Athanassios D Velentzas; Athanasios K Anagnostopoulos; Adamantia Agalou; Nikos C Papandreou; Stamatia A Katarachia; Dimitra G Koumoundourou; Eumorphia G Konstantakou; Vasiliki I Pantazopoulou; Anastasios Delis; Maria T Michailidi; Dimitrios Valakos; Dimitris Chatzopoulos; Popi Syntichaki; Vassiliki A Iconomidou; Ourania E Tsitsilonis; Issidora S Papassideri; Gerassimos E Voutsinas; Polydefkis Hatzopoulos; Dimitris Thanos; Dimitris Beis; Ema Anastasiadou; George Th Tsangaris; Dimitrios J Stravopodis
Journal:  Cancers (Basel)       Date:  2021-04-22       Impact factor: 6.639

Review 2.  Developing TRAIL/TRAIL death receptor-based cancer therapies.

Authors:  Xun Yuan; Ambikai Gajan; Qian Chu; Hua Xiong; Kongming Wu; Gen Sheng Wu
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

3.  Mammary tissue microenvironment determines T cell-dependent breast cancer-associated inflammation.

Authors:  Kei Takahashi; Nao Nagai; Keisuke Ogura; Koichi Tsuneyama; Ikuo Saiki; Tatsuro Irimura; Yoshihiro Hayakawa
Journal:  Cancer Sci       Date:  2015-05-29       Impact factor: 6.716

4.  PhiC31/PiggyBac modified stromal stem cells: effect of interferon γ and/or tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on murine melanoma.

Authors:  Vahid Bahrambeigi; Nafiseh Ahmadi; Stefan Moisyadi; Johann Urschitz; Rasoul Salehi; Shaghayegh Haghjooy Javanmard
Journal:  Mol Cancer       Date:  2014-11-26       Impact factor: 27.401

5.  Neurotensin receptor 1 signaling promotes pancreatic cancer progression.

Authors:  Kei Takahashi; Shogo Ehata; Kensuke Miyauchi; Yasuyuki Morishita; Keiji Miyazawa; Kohei Miyazono
Journal:  Mol Oncol       Date:  2020-11-20       Impact factor: 6.603

6.  IL-17A-producing CD30(+) Vδ1 T cells drive inflammation-induced cancer progression.

Authors:  Yoshitaka Kimura; Nao Nagai; Naoki Tsunekawa; Marimo Sato-Matsushita; Takayuki Yoshimoto; Daniel J Cua; Yoichiro Iwakura; Hideo Yagita; Futoshi Okada; Hideaki Tahara; Ikuo Saiki; Tatsuro Irimura; Yoshihiro Hayakawa
Journal:  Cancer Sci       Date:  2016-09-01       Impact factor: 6.716

7.  Anti‑inflammatory compounds moracin O and P from Morus alba Linn. (Sohakuhi) target the NF‑κB pathway.

Authors:  Besse Hardianti; Lin Umeyama; Feng Li; Satoru Yokoyama; Yoshihiro Hayakawa
Journal:  Mol Med Rep       Date:  2020-10-20       Impact factor: 2.952

8.  Ethyl P-Methoxycinnamate: An Active Anti-Metastasis Agent and Chemosensitizer Targeting NFκB from Kaempferia galanga for Melanoma Cells.

Authors:  Subehan Lallo; Besse Hardianti; Sartini Sartini; Ismail Ismail; Dewi Laela; Yoshihiro Hayakawa
Journal:  Life (Basel)       Date:  2022-02-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.